[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hyperglycaemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hyperglycaemia":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,77,106],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100599750","intermittent-versus-continuous-glucose-monitoring-in-intensive-care-unit-100599750",false,"NCT07088549","Intermittent Versus Continuous Glucose Monitoring in Intensive Care Unit","Effect of Continuous Interstitial Glucose Monitoring on Glycaemic Targets and Clinical Outcomes in Critically Ill","ICONS-ICU","Inclusion Criteria:\n\n* age ≥ 18 years\n* admission to the level 3 ICU\n* two consecutive blood glucose measurements \\> 10.0 mmol\u002FL\n* intravenous insulin therapy\n\nExclusion Criteria:\n\n* expected ICU stay \\\u003C 48 hours\n* pregnancy\n* type 1 diabetes\n* diabetic emergencies (DKA, DAHS)\n* severe skin disease\n* severe neutropenia (\\\u003C 0.5 × 10\\^9\u002FL)\n* severe coagulopathy (thrombocytes \\\u003C 20 × 10\\^9\u002FL)\n* manufacturer-defined conditions (hydroxyurea use, acetaminophen more than 4 g daily)","ALL","18 Years",{"count":20,"type":21},200,"ESTIMATED","INTERVENTIONAL",[24],"NA","Glucose control is an important part of supportive care for critically ill patients. Achieving optimal glucose control in such situations is challenging due to frequent fluctuations in blood glucose levels. These changes are often difficult to detect because the monitoring procedures are complex and require significant staff involvement, frequent blood draws, and consequent blood loss. Continuous glucose monitoring (CGM) is a simple and minimally invasive technique that has been approved and increasingly used by people with diabetes mellitus. However, its effectiveness in terms of glucose control management and accuracy in conditions with severe organ dysfunction has not been established.\n\nThe goal of this study is to assess the performance of CGM-guided glucose control in comparison to the standard glucose monitoring procedure. Additionally, the accuracy of CGM measurements under critical conditions will be evaluated against the standard of care.",[27,28,29],"Critical Illness","Hyperglycaemia","Hypoglycaemia",[31,32],"continuous glucose monitoring","icu","NOT_YET_RECRUITING","2025-07-19",{"date":36,"type":37},"2025-07-28","ACTUAL",{"date":39,"type":21},"2025-07",{"date":41,"type":21},"2026-12",{"name":43,"class":44},"University Medical Centre Ljubljana","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":61,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100595831","developing-an-ai-pharmacy-chatbot-for-the-population-of-hong-kong-100595831","NCT07037563","Developing an AI Pharmacy Chatbot for the Population of Hong Kong","Inclusion Criteria:\n\n* Patients aged 18 years or older diagnosed with either hyperglycaemia, hypertension, or hyperlipidaemia, and currently receiving medication prescribed by the Hospital Authority in Hong Kong.\n* Caregivers aged 18 years or older for patients described above.\n\nExclusion Criteria:\n\n* There is no exclusion criterion, but they should meet the inclusion criteria above.",true,{"count":54,"type":21},280,[24],"The primary objective of this study is to is to develop a conversational AI service (chatbot) in Hong Kong to assist patients and caregivers with inquires related to Hospital Authority (HA)-prescribed medications, and to evaluate its effectiveness in answering medication-related questions. The main questions it aims to answer are:\n\n1. How satisfied are the patients and caregivers with this pharmacy chatbot?\n2. How will the pharmacy chatbot impact eligible patients or caregivers on their (or the patient they are caring for) medication adherence, knowledge, and the consultation time with HA pharmacists?\n\nThere will be an intervention group and a control group:\n\n1. The intervention group will be invited to use the AI Pharmacy Chatbot online for 7 days through WhatsApp, a commonly used social media platform in Hong Kong. They can inquire about their medications prescribed under HA and get instant, validated answers from the chatbot.\n2. The control group will not use the chatbot during the intervention period.\n\nTo evaluate the chatbot's usability, researchers will measure patient satisfaction through usability questionnaires issued to the intervention group after their intervention period. Differences in medication adherence, medication knowledge, and HA pharmacist consultation time will also be measured between the intervention and control groups after the intervention period, to determine the chatbot's impact.",[28,58,59,60],"Hypertension","Hyperlipidaemia","Artificial Intelligence (AI)",[62,63,64,65],"Chatbot","Intelligent Conversational Agent","Artificial Intelligence","Implementation Science","RECRUITING","2025-06-17",{"date":69,"type":37},"2025-06-25",{"date":71,"type":21},"2025-06",{"date":73,"type":21},"2026-10-31",{"name":75,"class":44},"The University of Hong Kong",2,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":4},"100590808","glucose-levels-in-acute-pancreatitis-and-the-impact-of-insulin-depletion-and-bacterial-endotoxaemia-100590808","NCT06972238","Glucose Levels in Acute Pancreatitis and the Impact of Insulin Depletion and Bacterial Endotoxaemia","A Prospective Observational Study of Acute Pancreatitis Severity and the Association of Glucose Time in Range and Stress Hyperglycaemia, Plasma Insulin Depletion and Bacterial Endotoxaemia","GLIDE","Inclusion Criteria:\n\n1. Age 18 years or over\n2. Admission diagnosis of acute pancreatitis (based on Revised Atlanta Criteria)\n3. Ability to provide informed consent in English\n\nExclusion Criteria:\n\n1. Known diabetes mellitus\n2. Use of insulin therapy before admission\n3. Pregnancy\n4. Contraindications to CGM (e.g., allergy to device adhesive)",{"count":86,"type":21},30,"OBSERVATIONAL","There are currently no early predictive biomarkers for severity of acute pancreatitis (AP) that would allow stratification of patients for potential early interventional therapies. Hyperglycaemia is frequently observed to accompany and contribute to severe AP. However, the underlying mechanism is multifactorial, including in the acute phase of injury, where elevated adrenaline, cortisol and glucagon and inflammatory cytokine-induced insulin resistance all contribute to hyperglycaemia. The investigators propose that the extent of collateral injury of pancreatic β-cells and consequent loss of insulin secretion during the course of acute pancreatitis (AP) underlies disease severity. The investigators will measure plasma C-peptide (as a reliable readout of endogenous insulin), with moment-to-moment glucose monitoring (using subcutaneous continuous glucose monitoring devices), and bacterial endotoxin (lipopolysaccharide (LPS) in a prospective cohort of 30 severe AP patient blood samples taken every 5 days for up to 5 weeks of hospitalization.",[90,28],"Pancreatitis, Acute",[92,28,93,94,95],"Pancreatitis","inflammation","clinical severity","beta-cell","2025-05-16",{"date":98,"type":37},"2025-05-21",{"date":100,"type":21},"2025-12-01",{"date":102,"type":21},"2026-08-30",{"name":104,"class":105},"Manchester University NHS Foundation Trust","OTHER_GOV",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":116,"conditions":117,"keywords":119,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":129,"leadSponsor":131,"locationsCount":45},"100568030","continuous-glucose-monitoring-cgm-after-kidney-transplantation-100568030","NCT06675903","Continuous Glucose Monitoring (CGM) After Kidney Transplantation","Continuous Glucose Monitoring in Kidney Transplant Recipients with Diabetes, Pre-diabetes and Without Diabetes","CGM-KTx","Inclusion Criteria:\n\n* Written informed consent obtained before CGM application\n* Male or female; age: ≥18 years\n* Kidney transplantation\n\nExclusion Criteria:\n\n* Unable to cooperate to CGM the first ten days after surgery\n* Allergic to plasters in CGM units\n* Combined kidney and liver or pancreatic transplantation\n* Graft loss\u002Frejection within first 48 hours after transplantation",{"count":115,"type":21},54,"This study examines glucose levels measured by continuous glucose monitoring (CGM) in the immediate period following kidney transplantation among recipients with diabetes, without diabetes, and with pre-diabetes.\n\nThe primary objective is to analyse differences in mean sensor glucose between these three groups.\n\nCGMs are applied to participants within 72 hours after kidney transplantation, with a total of 54 participants divided equally across the three groups (18 in each).\n\nSecondary objectives include assessing additional glucose profile indices, adherence to relevant guidelines, changes in HbA1c, the impact of immunosuppression and steroid dosage, and beta cell function.",[28,118],"Kidney Transplantation",[120,121,122,123,31,124],"Kidney transplantation","diabetes","prediabetes","hyperglycaemia","CGM","2024-11-12",{"date":127,"type":37},"2024-11-13",{"date":125,"type":37},{"date":130,"type":21},"2026-01-01",{"name":132,"class":44},"Bo Feldt-Rasmussen"]